Delcath Systems, Inc. (DCTH): Price and Financial Metrics


Delcath Systems, Inc. (DCTH): $2.80

-0.05 (-1.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DCTH Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for DCTH is -0.8 -- better than merely 5.21% of US stocks.
  • DCTH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 92.98% of US stocks.
  • As for revenue growth, note that DCTH's revenue has grown 114.49% over the past 12 months; that beats the revenue growth of 92.72% of US companies in our set.
  • Stocks that are quantitatively similar to DCTH, based on their financial statements, market capitalization, and price volatility, are HRTX, AIP, SRNE, CRNC, and ATOM.
  • Visit DCTH's SEC page to see the company's official filings. To visit the company's web site, go to delcath.com.

DCTH Valuation Summary

  • DCTH's price/sales ratio is 5.8; this is 190% higher than that of the median Healthcare stock.
  • DCTH's price/sales ratio has moved up 4.8 over the prior 55 months.

Below are key valuation metrics over time for DCTH.

Stock Date P/S P/B P/E EV/EBIT
DCTH 2022-11-25 5.8 -4.7 -0.8 -0.9
DCTH 2022-11-23 6.0 -4.8 -0.8 -0.9
DCTH 2022-11-22 6.1 -4.8 -0.8 -1.0
DCTH 2022-11-21 6.0 -4.8 -0.8 -1.0
DCTH 2022-11-18 6.2 -5.0 -0.8 -1.0
DCTH 2022-11-17 5.9 -4.7 -0.8 -0.9

DCTH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DCTH has a Quality Grade of D, ranking ahead of 7.37% of graded US stocks.
  • DCTH's asset turnover comes in at 0.07 -- ranking 160th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows DCTH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.070 0.627 39.890
2021-03-31 0.067 0.613 14.650
2020-12-31 0.081 0.611 9.684
2020-09-30 0.109 0.569 1.033
2020-06-30 0.099 0.556 0.617
2020-03-31 0.132 0.563 0.458

DCTH Price Target

For more insight on analysts targets of DCTH, see our DCTH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.75 Average Broker Recommendation 1.25 (Strong Buy)

DCTH Stock Price Chart Interactive Chart >

Price chart for DCTH

DCTH Price/Volume Stats

Current price $2.80 52-week high $10.24
Prev. close $2.85 52-week low $2.34
Day low $2.77 Volume 13,700
Day high $2.85 Avg. volume 30,075
50-day MA $2.99 Dividend yield N/A
200-day MA $4.55 Market Cap 24.07M

Delcath Systems, Inc. (DCTH) Company Bio


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.


DCTH Latest News Stream


Event/Time News Detail
Loading, please wait...

DCTH Latest Social Stream


Loading social stream, please wait...

View Full DCTH Social Stream

Latest DCTH News From Around the Web

Below are the latest news stories about DELCATH SYSTEMS INC that investors may wish to consider to help them evaluate DCTH as an investment opportunity.

Delcath Systems (DCTH) Receives a Buy from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems (DCTH - Research Report), with a price target of $19.00. The company's shares closed yesterday at $2.80.According to TipRanks, Ramakanth is an analyst with an average return of -14.7% and a 28.76% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, MiMedx Group, and Ocugen.Delcath Systems has an analyst consensus of Moderate Buy, with a price target consensus of $19.00, which is a 578.57% upside from current levels. In a report released on November 8, BTIG also reiterated a Buy rating on the stock with a $19.00 price target.

Catie Powers on TipRanks | November 10, 2022

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH), announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to employment to two individuals. The employees received a total of 40,000 shares of the Company's common stock, outside of the Company's Amended and Restated 2020 Stock Incentive Plan ("Plan"). The options were issued upon the employee's grant date ("Grant Date"), and all stock options included within the equity inducement

Yahoo | November 9, 2022

Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2022.

Yahoo | November 8, 2022

Delcath Systems to Host Third Quarter 2022 Results

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 8, 2022, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2022.

Yahoo | October 24, 2022

Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C. Wainwright 24th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 12 at 8:30 AM ET.

Yahoo | September 1, 2022

Read More 'DCTH' Stories Here

DCTH Price Returns

1-mo -1.75%
3-mo -33.57%
6-mo -37.64%
1-year -71.25%
3-year -89.97%
5-year N/A
YTD -63.87%
2021 -56.75%
2020 -15.67%
2019 -89.16%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6985 seconds.